Achieve Life Sciences, Inc.
ACHV Healthcare Biotechnology
In the quarter to June 2026, EPS fell 116.2%, free cash flow fell 19.0% and total debt rose 63.9%, each against the same quarter a year earlier.
Follow ACHV
Achieve Life Sciences, Inc. (ACHV) Altman Z-score
Achieve Life Sciences, Inc.'s Altman Z-score for fiscal 2014 is −3.39, in the distress zone (below 1.81).
Altman Z-score, annual
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|
How fiscal 2014’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.60 | — | 0.72 | |
| Retained earnings / total assets | (2.84) | — | −3.98 | |
| EBIT / total assets | (0.52) | — | −1.73 | |
| Market value of equity / total liabilities | 1.86 | — | 1.11 | |
| Sales / total assets | 0.48 | — | 0.48 | |
| Altman Z-score | Distress zone | −3.39 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −7.26 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| FDMT 4D Molecular Therapeutics, Inc. compare | 2.5× |
| OABI OmniAb, Inc. compare | 2.5× |
| IVA Inventiva S.A. Sponsored ADR compare | −1.4× |
| ACHV Achieve Life Sciences, Inc. | −3.4× |
| LXRX Lexicon Pharmaceuticals, Inc. compare | −12.1× |
| ANL Adlai Nortye Ltd. Sponsored ADR compare | −22.1× |
| SANA Sana Biotechnology, Inc. compare | — |
| ANNX Annexon, Inc. compare | — |
| IMMX Immix Biopharma, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets